Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 1.75B | 2.05B | 2.24B | 2.18B | 1.61B |
Gross Profit | 693.60M | 840.29M | 771.00M | 855.37M | 655.91M |
EBITDA | -48.64M | 42.42M | -289.44M | 32.07M | -376.33M |
Net Income | -326.14M | -248.37M | -539.96M | -138.07M | -532.63M |
Balance Sheet | |||||
Total Assets | 2.55B | 2.78B | 3.09B | 3.42B | 2.45B |
Cash, Cash Equivalents and Short-Term Investments | 309.35M | 416.16M | 473.78M | 536.83M | 773.58M |
Total Debt | 645.94M | 995.01M | 1.01B | 839.04M | 762.34M |
Total Liabilities | 2.24B | 1.76B | 1.79B | 1.67B | 1.30B |
Stockholders Equity | 305.83M | 1.02B | 1.30B | 1.76B | 1.14B |
Cash Flow | |||||
Free Cash Flow | 28.99M | 16.15M | -164.27M | -190.88M | -198.98M |
Operating Cash Flow | 60.70M | 141.81M | 12.15M | -1.71M | 40.39M |
Investing Cash Flow | -92.11M | -77.14M | -182.11M | -959.06M | -351.32M |
Financing Cash Flow | -22.91M | -122.29M | 106.92M | 724.01M | 772.28M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
86 Outperform | 384.30M | 7.94 | 13.78% | 4.39% | 6.19% | -4.44% | |
59 Neutral | 563.80M | 54.15 | 7.27% | ― | 9.45% | -57.24% | |
52 Neutral | £552.49M | ― | -18.75% | ― | -20.36% | ― | |
46 Neutral | 331.79M | -1.13 | -64.97% | ― | -15.86% | -18.46% | |
46 Neutral | 689.09M | -71.72 | 33.36% | 0.47% | 2.62% | -129.82% | |
38 Underperform | 168.14M | -0.50 | -8369.23% | ― | -45.91% | -120.22% | |
61 Neutral | $18.38B | 12.79 | -2.54% | 3.03% | 1.52% | -15.83% |
THG PLC reported its interim results for the first half of 2025, showing a return to revenue growth in the second quarter, driven by strategic changes in its beauty and nutrition divisions. The company completed a successful demerger of THG Ingenuity and disposed of Claremont Ingredients, which, along with refinancing, improved its net cash position. Despite a slight decline in overall group revenue, THG anticipates stronger performance in the second half, supported by increased brand partnerships and market share gains, particularly in the UK beauty sector and Myprotein’s expansion in offline retail and licensing.
The most recent analyst rating on (GB:THG) stock is a Hold with a £29.00 price target. To see the full list of analyst forecasts on THG stock, see the GB:THG Stock Forecast page.
THG PLC announced that it will release its interim results for the six months ending 30 June 2025 on 11 September 2025. This announcement is significant for stakeholders as it provides insights into the company’s financial performance and strategic direction, potentially impacting its market positioning and investor confidence.
The most recent analyst rating on (GB:THG) stock is a Hold with a £29.00 price target. To see the full list of analyst forecasts on THG stock, see the GB:THG Stock Forecast page.
THG PLC has announced that Sue Farr, currently serving as the Senior Independent Director, will be joining Vistry Group PLC as a non-executive director starting from October 1, 2025. This move signifies a strategic alignment and potential collaboration between the two companies, which could influence THG’s market positioning and stakeholder relations.
The most recent analyst rating on (GB:THG) stock is a Hold with a £29.00 price target. To see the full list of analyst forecasts on THG stock, see the GB:THG Stock Forecast page.
THG PLC has announced the sale of Claremont Ingredients, a UK-based flavour manufacturing and development laboratory, to Nactarome Group for approximately £103 million. This move aligns with THG’s strategy to simplify its operations and achieve a net cash balance sheet. The sale represents a significant return on investment, as Claremont was originally acquired for £52 million in 2020. Financially, the disposal will aid in reducing THG’s net leverage and borrowing costs. Operationally, the relationship with Claremont will continue through a long-term supply contract, ensuring Myprotein’s flavour capabilities remain robust. The transaction is expected to impact THG’s EBITDA in the coming years, but the company anticipates double-digit revenue growth for THG Nutrition in the second half of 2025, driven by stable whey prices and strategic pricing approaches to enhance market share.
The most recent analyst rating on (GB:THG) stock is a Sell with a £0.49 price target. To see the full list of analyst forecasts on THG stock, see the GB:THG Stock Forecast page.
THG PLC has announced the sale of Claremont Ingredients, a UK-based flavour manufacturing and development laboratory, to Nactarome Group for approximately £103 million. This divestment aligns with THG’s strategy to simplify its operations and achieve a net cash balance sheet. The sale represents a significant return on investment, as Claremont was acquired for £52 million in 2020. Financially, the disposal will help reduce THG’s net leverage and borrowing costs, although it is expected to decrease the Group’s EBITDA for FY 2025 and FY 2026 by £5 million and £10 million, respectively. The strategic move is part of THG’s broader plan to focus on core strengths and market share growth, particularly for its Myprotein brand, which is expected to see double-digit revenue growth in the second half of 2025.
The most recent analyst rating on (GB:THG) stock is a Sell with a £0.49 price target. To see the full list of analyst forecasts on THG stock, see the GB:THG Stock Forecast page.
THG PLC has announced changes to its Board Committee memberships. Milyae Park, an independent Non-Executive Director, has been appointed to the Audit and Risk Committees and the Sustainability Committee. Additionally, Helen Jones, another independent Non-Executive Director, will now serve as the designated Non-Executive Director for workforce engagement. These changes are expected to enhance the company’s governance and engagement with its workforce, potentially impacting its operational efficiency and stakeholder relations.
The most recent analyst rating on (GB:THG) stock is a Sell with a £0.49 price target. To see the full list of analyst forecasts on THG stock, see the GB:THG Stock Forecast page.